Panelists discuss how recent advancements in frontline and second-line therapies for unrespectable hepatocellular carcinoma (uHCC) are reshaping treatment strategies and improving patient outcomes.
October 7th 2024
Panelists discuss the current landscape of first-line treatment for unresectable hepatocellular carcinoma, highlighting key options and decision-making factors.
Panelists discuss current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions.
October 18th 2024
Panelists discuss the circumstances under which monotherapy with a tyrosine kinase inhibitor or immunotherapy would be preferred in the treatment of unresectable hepatocellular carcinoma.
October 25th 2024
Panelists discuss the findings from the EMERALD-1 trial on durvalumab with or without bevacizumab combined with transarterial chemoembolization TACE for first-line treatment of unresectable hepatocellular carcinomaHCC, examining its implications on progression-free survival, safety, and outcomes based on baseline tumor burden.
Panelists discuss the findings from the LEAP-012 study, which explores the efficacy of transarterial chemoembolization combined with lenvatinib and pembrolizumab in patients with Child-Pugh class A disease and intermediate-stage hepatocellular carcinoma.
Panelists discuss the results of the LEAP-012 study, highlighting the efficacy of transarterial chemoembolization combined with lenvatinib and pembrolizumab in patients with intermediate-stage hepatocellular carcinoma and Child-Pugh class A disease.